Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab in Adults With de Novo Minimal Change Disease
NCT07710157Phase 2Recruiting
- Sponsor
- Medical University of Innsbruck
- Start
- Jul 2026
- Primary completion
- Jun 2028
- Countries
- 3
01
Overview
A Phase 2 trial of obinutuzumab in minimal change disease (MCD), sponsored by Medical University of Innsbruck. Started Jul 2026; status: recruiting.
02
Drugs
obinutuzumab
03
Conditions
minimal change disease (MCD)
Beyond the preview
Go deeper on NCT07710157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07710157.